To get around the immune system, nanoparticles are disguised as red blood cells

One of the key goals in the field of cancer drug administration has long been the creation of nanoparticle platforms with lengthy in vivo circulation half-lives. Longcirculating nanoparticles can better target the tumour site through passive or active targeting processes. PEG, which surrounds the particles with a hydration layer and so resists recognition by the mononuclear phagocyte system, is the current gold standard for bestowing long-circulating characteristics. The body’s own long-circulating organisms, Red Blood Cells (RBCs), have recently inspired a new technique for producing biomimetic nanoparticles. Using membrane components produced directly from RBCs, this approach disguises drug nanocarriers as self. This approach has been shown to extend the half-life of particles in the systemic circulation beyond that of PEGylated systems. The RBC membrane-coated nanoparticles represent a significant advancement in drug delivery technology and hold a lot of promise for therapeutic use. We discuss the relevance and unique characteristics of this nature-inspired nanoparticle technology, as well as our thoughts on its future prospects.